Nanoviricides market cap has taken a beating in the past few days due to the global equities bear market and a temporary and apparently innocuous "E" added to the end of the symbol. The Company put out a press release today, saying in relevant part:
The “E” reflects that the Company has not yet filed its Form 10-KSB, annual report to shareholders. The Company’s symbol will return to NNVC.OB once the Form 10-KSB is filed. The Company anticipates it will file our annual report within the time provided and expects there to be no significant change in its financial statements.Commenting on this event, Eugene Seymour, MD, MPH, the Company’s Chief Executive Officer, stated “We want to assure our stockholders that nothing about the Company has changed. We remain committed to both our mission and our science and we will rectify this issue within ten days.As for me, I've been buying NNVC under $1.00 and now under $0.75, adding to my positions. This is a rare opportunity to buy a stock on the cusp of significant company developments with global health ramifications. We have been given hints of substantial HIV progress that has yet to hit the media, but make no mistake, once it does, available shares will dry up as this stock will be bid up above previous all time highs.
Following recently disclosed successful financing, we are now busy scheduling the follow-on studies against HIV as well as adenoviral EKC. We have received significant interest from several major pharmaceutical companies, as well as governmental and non-profit institutions for nanoviricides development against these diseases,” he further added.
“We are now gathering significant and valuable input for these studies from important stakeholders interested in furthering development of highly effective drugs against these major diseases,” said Anil R. Diwan, PhD, President of the Company.